| P50 | author | Antoni Serrano-Blanco | Q43088197 |
| | Luiz Alberto Lira Soares | Q55404750 |
| P2093 | author name string | Aurigena Antunes de Araújo | |
| | Maria do Socorro Costa Feitosa Alves | |
| | Raimundo Fernandes de Araújo Júnior | |
| | Gerlane Coelho Bernardo Guerra | |
| | Katarina Melo Chaves | |
| | Susana Barbosa Ribeiro | |
| | Antônio Filgueira Júnior | |
| | Vanessa de Paula Soares Rachetti | |
| P2860 | cites work | Schizophrenia and quality of life: how important are symptoms and functioning? | Q34468429 |
| | Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study | Q34576579 |
| | Associated factors of quality of life in first-episode schizophrenia patients | Q35238330 |
| | Mechanisms of action of second generation antipsychotic drugs in schizophrenia: insights from brain imaging studies | Q36005352 |
| | A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP) | Q37172973 |
| | Antipsychotics and schizophrenia: from efficacy and effectiveness to clinical decision-making | Q37725147 |
| | The relationship between quality of life and clinical efficacy from a randomized trial comparing olanzapine and ziprasidone. | Q38403241 |
| | Antipsychotic induced hyperprolactinaemia: a series of illustrative case reports | Q43841264 |
| | A preliminary study of the comparative effects of olanzapine and risperidone on cognition in schizophrenia | Q44924777 |
| | Subjective quality of life in patients with chronic schizophrenia: relationships between psychosocial and clinical characteristics | Q45011151 |
| | Quality of life outcomes of risperidone, olanzapine, and typical antipsychotics among schizophrenia patients treated in routine clinical practice: a naturalistic comparative study | Q46227460 |
| | Quality of life and cognitive dysfunction in people with schizophrenia | Q49062968 |
| | Declaration of Helsinki. | Q53496190 |
| | Cellular mechanisms involved in the melatonin inhibition of HT-29 human colon cancer cell proliferation in culture | Q60585565 |
| | The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients | Q69903875 |
| | The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome | Q70601646 |
| | [Safety and tolerability of olanzapine versus risperidone: a one-year randomized study in outpatients with schizophrenia with prominent negative symptoms] | Q80080118 |
| | Quality of life of psychiatric patients | Q82499967 |
| | Effectiveness and safety of antipsychotics in early onset psychoses: a long-term comparison | Q84097564 |
| | [Effectiveness of antipsychotics in schizophrenia and related disorders. Results of a naturalistic study] | Q84938564 |
| P433 | issue | 1 | |
| P921 | main subject | schizophrenia | Q41112 |
| | risperidone | Q412443 |
| P304 | page(s) | 125-135 | |
| P577 | publication date | 2013-03-01 | |
| P1433 | published in | Psychiatric Quarterly | Q7256226 |
| P1476 | title | Quality of life and adverse effects of olanzapine versus risperidone therapy in patients with schizophrenia | |
| P478 | volume | 84 | |